Effect of nesiritide versus dobutamine for treatment of acutely decompensated heart failure on cardiovascular adverse events
Andrew J. Burger(Beth Israel Deaconess Medical Center), Darlene P. Horton(Napo Pharmaceuticals (United States)), Allen D. Johnson(Scripps Health)
Cited by 3
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
|American Heart Journal|2002|323
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
|Journal of the American College of Cardiology|1999|323
Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure
|Journal of the American College of Cardiology|2002|232